Clinical trials: Breast Cancer, Metastatic Breast Cancer
HER2-positive Breast Cancer, Postmenopausal
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
Survival benefit and quality of life are two key elements that should be kept in mind in the treatment of metastatic breast cancer.
- Conditions
- HER2-positive Breast Cancer, Postmenopausal, Metastatic Breast Cancer
- Trial name
- NCT03913234
- Testing
- Ribociclib, Trastuzumab, Letrozole
- Where
- South Korea
- Volunteers
- 95 people
- Sponsor
- Yonsei University
Breast Cancer
Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00002498
- Testing
- CMF regimen, cyclophosphamide, fluorouracil
- Where
- 2 sites in Netherlands
- Sponsor
- Leiden University Medical Center
Triple-Negative Breast Neoplasms, Breast Neoplasm
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and…
- Conditions
- Triple-Negative Breast Neoplasms, Breast Neoplasm, Breast Cancer, Triple-Negative Breast Cancer
- Trial name
- NCT02978716
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 102 people
- Sponsor
- G1 Therapeutics, Inc.
Breast Cancer
Exploratory Study of Breast Cancer With ABY025
The aim is to study if breast cancer metastases accumulate the newly developed HER2 binding molecule 111-In-ABY025 and if that shows whether the metastases express HER2.
- Trial name
- ABY0125 (NCT01216033)
- Testing
- 111-In-ABY-025
- Where
- Sweden
- Volunteers
- 7 people
- Sponsor
- Biomedical Radiation Sciences
TNBC, TNBC - Triple-Negative Breast Cancer
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
This Expanded Access Program provides investigational access to leronlimab (PRO 140) for patients with advanced or metastatic triple-negative breast cancer (TNBC) who lack satisfactory treatment options and are unable to…
- Conditions
- TNBC, TNBC - Triple-Negative Breast Cancer, TNBC, Triple Negative Breast Cancer
- Trial name
- NCT07536815
- Testing
- leronlimab (PRO 140)
- Where
- United States
- Sponsor
- CytoDyn, Inc.
Metastases to Bone, Metastatic Breast Cancer
Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study
Osteolytic bone metastases and myeloma bone lesions are responsible of long bone and vertebral fractures leading to restricted mobility, surgery and medullar compression that severely alter quality of life and that have a huge…
- Conditions
- Metastases to Bone, Metastatic Breast Cancer, Metastatic NSCLC
- Trial name
- MEKANOS (NCT04170634)
- Testing
- Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation
- Where
- 12 sites in France
- Volunteers
- 220 people
- Sponsor
- Hospices Civils de Lyon
Bladder Cancer, Brain and Central Nervous System Tumors
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer
- Trial name
- NCT00313599
- Testing
- lapatinib, paclitaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Breast Cancer, Advanced Breast Cancer
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one…
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
- Trial name
- OPERA-01 (NCT06016738)
- Testing
- Palazestrant, Fulvestrant, Anastrozole
- Where
- 233 sites in United States, Argentina and 24 more
- Volunteers
- 510 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Breast Cancer
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer
This is a phase 2 study of bosutinib administered in combination with letrozole versus letrozole alone in post-menopausal women with breast cancer. This is a 2-part study.
- Trial name
- NCT00880009
- Testing
- Bosutinib, Letrozole
- Where
- 11 sites in United States, Belgium and 5 more
- Volunteers
- 16 people
- Sponsor
- Pfizer
Breast Cancer
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
This trial studies the effects on quality of life and on time to second progression of the sequence endocrine therapy-capecitabine versus the sequence capecitabine-endocrine treatment.
- Trial name
- NCT00684216
- Testing
- capecitabine, hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- The Netherlands Cancer Institute
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
This early phase I trial tests the safety and side effects of ZN-c3 in treating patients with triple-negative breast cancer or ovarian cancer that have spread to other parts of the body (metastatic or advanced).
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT05368506
- Testing
- Wee1 Inhibitor ZN-c3
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
This is a Phase I/II study to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics following daily oral doses of 50 to 200 mg of BMS-754807 in combination with trastuzumab (Herceptin®) in subjects with…
- Trial name
- NCT00788333
- Testing
- BMS-754807, trastuzumab (Herceptin®)
- Where
- 9 sites in Australia, Belgium and 3 more
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Painful Bone Metastases, Breast Carcinoma
MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases
This study will evaluate treatment with High Intensity Focused Ultrasound (HIFU)in combination with ThermoDox (liposomal doxorubicin) is safe and effective in reducing pain for patients with painful bone metastases.
- Conditions
- Painful Bone Metastases, Breast Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01640847
- Testing
- High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox
- Sponsor
- Imunon
Metastatic Breast Cancer
A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
The purpose of this study is to assess the efficacy of a PARP inhibitor, rucaparib, in progressing breast cancer patients and who are carrying a BCRAness profile defined by genomic signature or BRCA 1 or 2 somatic mutation…
- Trial name
- RUBY (NCT02505048)
- Testing
- rucaparib
- Where
- 2 sites in France
- Volunteers
- 41 people
- Sponsor
- UNICANCER
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Advanced Solid Tumors, HER2-positive Breast Cancer
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors.
- Trial name
- NCT04487236
- Testing
- ZN-A-1041 50mg BID, ZN-A-1041 100mg BID, ZN-A-1041 200mg BID
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Suzhou Zanrong Pharma Limited
Breast Cancer
GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting
Non-interventional, multicenter, prospective observational study of tucatinib-trastuzumab capecitabine administered according to the standard local clinical practice following approved SmPC indication and dose.
- Trial name
- THERapy (NCT07583485)
- Where
- 30 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Oncotech
Metastatic Breast Cancer
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
This phase III trial aims to compare the efficacy and safety of fulvestrant or capecitabine as maintenance therapy after first-line chemotherapy in hormone receptor-positive, human epidermal growth factor receptor-2 negative…
- Trial name
- NCT04263298
- Testing
- Fulvestrant, Capecitabine Oral Product
- Where
- 13 sites in China
- Volunteers
- 210 people
- Sponsor
- Herui Yao
Breast Cancer
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- HORGEN (NCT00871858)
- Testing
- anastrozole, fulvestrant
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut Bergonié
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.